Ignite Creation Date:
2024-05-06 @ 1:16 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03971747
Status:
UNKNOWN
Last Update Posted:
2020-04-07
First Post:
2019-05-28
Brief Title:
AFP Specific T Cell Receptor Transduced T Cells InjectionC-TCR055 in Unresectable Hepatocellular Carcinoma
Sponsor:
Cellular Biomedicine Group Ltd
Organization:
Cellular Biomedicine Group Ltd
Study Overview
Official Title:
A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
Status:
UNKNOWN
Status Verified Date:
2020-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients
Detailed Description:
This study plans to enroll 9 patients to assess the safety of C-TCR055 Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection and will be followed up post treatment for safety monitoring The follow up period will last 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None